Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Stock Information for SpeakEasy Cannabis Club Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About SpeakEasy Cannabis Club Ltd.

Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their Rights
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc. (SKYE) Shareholders
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
ROSEN, A LONGSTANDING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SKYE
SKYE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Skye Bioscience, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Portnoy Law Firm Announces Class Action on Behalf of Skye Bioscience, Inc. Investors
Berger Montague PC Investigating Claims on Behalf of Skye Bioscience, Inc. (NASDAQ: SKYE) Investors After Class Action Filing

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.